Difference between revisions of "Part:BBa K4245007"
RichardJiang (Talk | contribs) |
RichardJiang (Talk | contribs) |
||
| Line 2: | Line 2: | ||
__NOTOC__ | __NOTOC__ | ||
<partinfo>BBa_K4245007 short</partinfo> | <partinfo>BBa_K4245007 short</partinfo> | ||
| + | <br> | ||
<br> | <br> | ||
This part is the sequence for hsa-miR-122-5p, an miRNA isolated from <i> Homo sapiens </i>. This miRNA acts as a dysregulated biomarker for coronary artery disease (Kaur et al., 2020), and is therefore potentially useful for the early detection of this condition. More specifically, hsa-miR-122-5p, or miRNA-122-5p, is seen to be a marker of the atherosclerotic process or metabolic profile underlying atherosclerosis (Singh et al., 2020). Furthermore, our call with Dr. Searles confirmed that hsa-miR-122-5p is a suitable biomarker to measure the development of CAD. As such, utilizing miRNA-122-5p has the potential to track the progression of coronary artery disease, indicating how far atherosclerosis has developed within a patient. | This part is the sequence for hsa-miR-122-5p, an miRNA isolated from <i> Homo sapiens </i>. This miRNA acts as a dysregulated biomarker for coronary artery disease (Kaur et al., 2020), and is therefore potentially useful for the early detection of this condition. More specifically, hsa-miR-122-5p, or miRNA-122-5p, is seen to be a marker of the atherosclerotic process or metabolic profile underlying atherosclerosis (Singh et al., 2020). Furthermore, our call with Dr. Searles confirmed that hsa-miR-122-5p is a suitable biomarker to measure the development of CAD. As such, utilizing miRNA-122-5p has the potential to track the progression of coronary artery disease, indicating how far atherosclerosis has developed within a patient. | ||
| Line 18: | Line 19: | ||
<br> | <br> | ||
Singh, S., de Ronde, M., Kok, M., Beijk, M. A., De Winter, R. J., van der Wal, A. C., Sondermeijer, B. M., Meijers, J., Creemers, E. E., & Pinto-Sietsma, S. J. (2020). MiR-223-3p and miR-122-5p as circulating biomarkers for plaque instability. Open heart, 7(1), e001223. https://doi.org/10.1136/openhrt-2019-001223 | Singh, S., de Ronde, M., Kok, M., Beijk, M. A., De Winter, R. J., van der Wal, A. C., Sondermeijer, B. M., Meijers, J., Creemers, E. E., & Pinto-Sietsma, S. J. (2020). MiR-223-3p and miR-122-5p as circulating biomarkers for plaque instability. Open heart, 7(1), e001223. https://doi.org/10.1136/openhrt-2019-001223 | ||
| + | <br> | ||
<br> | <br> | ||
<!-- Add more about the biology of this part here | <!-- Add more about the biology of this part here | ||
Revision as of 23:39, 10 October 2022
hsa-miR-122-5p
This part is the sequence for hsa-miR-122-5p, an miRNA isolated from Homo sapiens . This miRNA acts as a dysregulated biomarker for coronary artery disease (Kaur et al., 2020), and is therefore potentially useful for the early detection of this condition. More specifically, hsa-miR-122-5p, or miRNA-122-5p, is seen to be a marker of the atherosclerotic process or metabolic profile underlying atherosclerosis (Singh et al., 2020). Furthermore, our call with Dr. Searles confirmed that hsa-miR-122-5p is a suitable biomarker to measure the development of CAD. As such, utilizing miRNA-122-5p has the potential to track the progression of coronary artery disease, indicating how far atherosclerosis has developed within a patient.
The Lambert_GA 2022 team developed a set of padlock probes to use the rolling circle amplification approaches for several miRNAs related to CAD. This miRNA is used as the basis for BBa_K4245101 and BBa_K4245108, the 3' arm for hsa-miR-122-5p and 5' arm for hsa-miR-122-5p, and as the target sequence for BBa_K4245202, the hsa-miR-122-5p RCA Padlock Probe.
.
When using rolling circle amplification (RCA), the miRNA binds to the padlock. A rolling circle product (RCP) is produced from BBa_K4245130 (Middle Sequence), which is then detected by the linear probes BBa_K4245130 (Fluorophore) and BBa_K4245132 (Quencher). When these parts bind to the RCP, the fluorescence decreases. Therefore, lower fluorescence is indicative of greater miRNA concentrations.
References:
Kaur, A., Mackin, S. T., Schlosser, K., Wong, F. L., Elharram, M., Delles, C., Stewart, D. J., Dayan, N., Landry, T., & Pilote, L. (2020). Systematic review of microRNA biomarkers in acute coronary syndrome and stable coronary artery disease. Cardiovascular research, 116(6), 1113–1124. https://doi.org/10.1093/cvr/cvz302
Singh, S., de Ronde, M., Kok, M., Beijk, M. A., De Winter, R. J., van der Wal, A. C., Sondermeijer, B. M., Meijers, J., Creemers, E. E., & Pinto-Sietsma, S. J. (2020). MiR-223-3p and miR-122-5p as circulating biomarkers for plaque instability. Open heart, 7(1), e001223. https://doi.org/10.1136/openhrt-2019-001223
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]